On Friday shares of Cerus Corporation (NASDAQ:CERS) closed at $4.10. Company’s sales growth for last 5 years was 15.10%. Cerus Corporation (NASDAQ:CERS) on March 16, 2015, released that the first patient has been enrolled in its TReatment UsE (TRUE) study to make the INTERCEPT Blood System for platelets available to regions in the United States with outbreaks of chikungunya and dengue virus under an Expanded Access Investigational Device Exemption (IDE).
Sangamo Biosciences Inc. (NASDAQ:SGMO) in last trading activity advanced 4.23% to close at $15.54. Company weekly performance is -11.85% while its quarterly performance stands at 9.44%. Sangamo Biosciences Inc. (NASDAQ:SGMO) is -19.27% away from its 52 week high. analysts at Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Sangamo Biosciences Inc. (NASDAQ:SGMO) in a research note.
On last trading day Juniper Networks, Inc. (NYSE:JNPR) moved down -0.09% to close at $22.29. Its volatility for the week is 2.05% while volatility for the month is 1.89%. JNPR’s sales growth for past 5 years was 6.90% and its EPS growth for past 5 years was -39.70%. Juniper Networks, Inc. (NYSE:JNPR) monthly performance is -7.55%. On 23 March 2015, Mirantis Inc. announced the integration of Contrail, a software-defined networking (SDN) overlay platform from Juniper Networks Inc. (NYSE:JNPR), into its “pure-play” OpenStack distribution.
On last trading day Johnson & Johnson (NYSE:JNJ) moved up 0.20% to close at $100.34. Its volatility for the week is 1.32% while volatility for the month is 1.34%. JNJ’s sales growth for past 5 years was 3.70% and its EPS growth for past 5 years was 5.30%. Johnson & Johnson (NYSE:JNJ) monthly performance is -2.39%. Johnson & Johnson (NYSE:JNJ) will develop robotic surgical devices through a collaboration with Google Inc the company said Friday.
On last trading day Novogen Limited (NASDAQ:NVGN) increased 20.69% to close at $4.55. Its volatility for the week is 13.23% while volatility for the month is 11.33%. NVGN’s EPS growth for past 5 years was 23.80%. Novogen Limited (NASDAQ:NVGN) monthly performance is 69.78%. Novogen Ltd. (NASDAQ:NVGN) announced on 18th March, 2015, that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell’s cytoskeleton can deliver a powerful anti-cancer effect.